In the last twelve months, HOOKIPA Pharma generated $7.6 million in revenue and had a net loss of $16.2 million. The company has a market-cap of $391.1 million.
BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.
HOOKIPA Pharma provided the following description of their company for its IPO: ” We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on our proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our “off-the-shelf” technologies, VaxWave and TheraT, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels previously not achieved by other published immunotherapy approaches. Our lead infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Our lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. “.
HOOKIPA Pharma was founded in 2011 and has 60 employees. The company is located at 350 Fifth Avenue, 72nd Floor, New York, NY 10118, US and can be reached via phone at +43 1 890 63 60 or on the web at http://www.hookipapharma.com.
Receive News & Ratings for HOOKIPA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HOOKIPA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.